The
Calprotectin Testing Market features a competitive landscape characterized by innovation and strategic partnerships. Key players include Thermo Fisher Scientific, F. Hoffmann-La Roche AG, Abbott Laboratories, BioRad Laboratories, Siemens Healthineers, and Calpro AS.
Recent strategic developments include Thermo Fisher Scientific's March 2025 partnership with Mayo Clinic Laboratories to co-develop automated calprotectin testing workflows across U.S. and Canadian GI networks. Abbott Laboratories expanded its portfolio through the December 2024 acquisition of MediKine, broadening its fecal calprotectin and GI biomarker offerings. Roche launched a new fecal calprotectin assay on its cobas platform in May 2025, designed to improve turnaround times and laboratory integration.
The market is segmented by test type into qualitative, quantitative, and semi-quantitative testing, with quantitative testing valued at $300 million in 2024. End users span hospitals, diagnostic laboratories, and research institutions. Companies compete on regulatory approvals, cost-effectiveness, and user-friendly product design, with innovation in non-invasive testing methods remaining a critical differentiator.
FAQ
Q1: Who are the major players in the calprotectin testing market? A: Key players include Thermo Fisher Scientific, Roche, Abbott Laboratories, BioRad, and Siemens Healthineers.
Q2: What recent acquisition occurred in this market? A: Abbott Laboratories acquired MediKine in December 2024 to expand its GI biomarker portfolio.
Q3: What is the value of the quantitative testing segment? A: Quantitative testing was valued at $300 million in 2024.
About SPORTIVO Network
Czech
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Greek